Full profile
| Also known as | Pyrroloquinoline quinone, BioPQQ |
|---|---|
| Best for | Mitochondrial-support interest (cognition/fatigue, preliminary) |
| Evidence grade | Emerging: mostly preclinical or preliminary human data |
| Studied dose range | 20 mg/day. |
| Time to effect | Studies generally run several weeks of daily use. |
| Best form | BioPQQ, the most-studied branded form. |
Evidence, honestly graded
Positive human trials exist but are single-sponsor: all run on the BioPQQ branded ingredient, funded by its developer, with no independent replication published yet. Mechanistically plausible as a mitochondrial-biogenesis cofactor, but the human evidence base is too narrow and too concentrated to grade higher.
See the full grading rubric (study type, replication, population match, and dose adequacy) in The Evidence Standard.
Side effects
- Generally well tolerated
Who should avoid it or check first
- Pregnant or breastfeeding without clinician guidance (limited data)
Interactions
- Limited interaction data; discuss with a clinician if on medication
Stacks well with
- Acetyl-L-Carnitine (mechanistic mitochondrial pairing, not clinically proven as a combination)
What to look for on a label
- Specify the BioPQQ branded form. This is the material behind essentially all the human data.
References
- BioPQQ human cognition/fatigue trials. Single-sponsor (BioPQQ-funded) trials report positive effects on cognition and fatigue measures; no independent replication published to date. Educational, not a product claim.
Entries above without a linked identifier are either editorial summaries of a wider body of literature or references to a named authority (a regulator or government monograph) cited by name rather than by a single paper.
Grades and studied doses are our conservative reading of the human research, shown for education. They are not product claims, and a studied dose is not a recommended dose.
Revision history
Every change to this ingredient's evidence status, dated and explained. The full cross-library log lives at Evidence Updates.
- 2026-07-07New profile
Initial profile published at Grade Emerging: positive human trials are all single-sponsor on one branded ingredient, with no independent replication published yet.
See how PQQ compares on grade, dose, and goal in the Evidence Explorer.